MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer

References

• Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. doi:10.1101/cshperspect.a030361
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79–92. doi:10.1038/s41585-020-00400-w
   PubMed Web of Science ®Google Scholar
• Bancroft EK, Page EC, Brook MN, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol. 2021;22(11):1618–1631. doi:10.1016/s1470-2045(21)00522-2
   PubMed Web of Science ®Google Scholar
• Fasulo V, Zuradelli M, Lazzeri M. Re: a prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Eur Urol. 2022;81(2):216–218. doi:10.1016/j.eururo.2021.11.030
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Lei X, Lei Y, Li JK, et al. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–133. doi:10.1016/j.canlet.2019.11.009
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi:10.1093/annonc/mdw168
   PubMed Web of Science ®Google Scholar
• Gaballa MR, Ramos CA. Cellular immunotherapy in lymphoma: beyond CART cells. Curr Treat Options Oncol. 2020;21(3):21. doi:10.1007/s11864-020-0709-3
   PubMed Web of Science ®Google Scholar
• Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett. 2020;470:8–17. doi:10.1016/j.canlet.2019.12.002
   PubMed Web of Science ®Google Scholar
• Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: the current scenario and future perspectives. Cancer Treat Rev. 2020;88:102030. doi:10.1016/j.ctrv.2020.102030
   PubMed Web of Science ®Google Scholar
• Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Cancer Netw. 2020;18(4):479–489. doi:10.6004/jnccn.2020.7554
   PubMed Web of Science ®Google Scholar
• Cha HR, Lee JH, Ponnazhagan S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 2020;80(8):1615–1623. doi:10.1158/0008-5472.Can-19-2948
   PubMed Web of Science ®Google Scholar
• Fujii K, Murase T, Beppu S, et al. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. HistoPathology. 2017;71(5):823–834. doi:10.1111/his.13281
   PubMed Web of Science ®Google Scholar
• Cicirò Y, Sala A. MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis. 2021;10(2):19. doi:10.1038/s41389-021-00309-y
   PubMed Web of Science ®Google Scholar
• Malaterre J, Mantamadiotis T, Dworkin S, et al. c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Stem Cells. 2008;26(1):173–181. doi:10.1634/stemcells.2007-0293
   PubMed Web of Science ®Google Scholar
• Suetaka S, Oka Y, Kunihara T, Hayashi Y, Arai M. Rational design of a helical peptide inhibitor targeting c-Myb-KIX interaction. Sci Rep. 2022;12(1):816. doi:10.1038/s41598-021-04497-w
   PubMed Web of Science ®Google Scholar
• Zorbas M, Sicurella C, Bertoncello I, et al. c-Myb is critical for murine colon development. Oncogene. 1999;18(42):5821–5830. doi:10.1038/sj.onc.1202971
   PubMed Web of Science ®Google Scholar
• Trauth K, Mutschler B, Jenkins NA, Gilbert DJ, Copeland NG, Klempnauer KH. Mouse A-myb encodes a trans-activator and is expressed in mitotically active cells of the developing central nervous system, adult testis and B lymphocytes. EMBO J. 1994;13(24):5994–6005. doi:10.1002/j.1460-2075.1994.tb06945.x
   PubMed Web of Science ®Google Scholar
• Martinez I, Dimaio D. B-Myb, cancer, senescence, and microRNAs. Cancer Res. 2011;71(16):5370–5373. doi:10.1158/0008-5472.Can-11-1044
   PubMed Web of Science ®Google Scholar
• Joaquin M, Watson RJ. Cell cycle regulation by the B-Myb transcription factor. Cell Mol Life Sci. 2003;60(11):2389–2401. doi:10.1007/s00018-003-3037-4
   PubMed Web of Science ®Google Scholar
• Musa J, Aynaud MM, Mirabeau O, Delattre O, Grünewald TG. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8(6):e2895. doi:10.1038/cddis.2017.244
   PubMed Web of Science ®Google Scholar
• Chen X, Lu Y, Yu H, et al. Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene. Cell Cycle. 2021;20(21):2291–2308. doi:10.1080/15384101.2021.1982494
   PubMed Web of Science ®Google Scholar
• Bar-Shira A, Pinthus JH, Rozovsky U, et al. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002;62(23):6803–6807.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang M, Hu Y, et al. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer. Theranostics. 2021;11(12):5794–5812. doi:10.7150/thno.56604
   PubMed Web of Science ®Google Scholar
• Li X, Jiao M, Hu J, et al. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4. Prostate. 2020;80(9):674–686. doi:10.1002/pros.23979
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Ito K, Murphy D. Application of ggplot2 to Pharmacometric Graphics. CPT Pharmacomet Syst Pharmacol. 2013;2(10):e79–e. doi:10.1038/psp.2013.56
   PubMedGoogle Scholar
• Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12(1):77. doi:10.1186/1471-2105-12-77
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–380. doi:10.3978/j.issn.2223-4683.2015.05.02
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Gao WQ. The evolving role of immune cells in prostate cancer. Cancer Lett. 2021;525:9–21. doi:10.1016/j.canlet.2021.10.027
   PubMed Web of Science ®Google Scholar
• Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728–732. doi:10.1038/nature21676
   PubMed Web of Science ®Google Scholar
• Hou X, Zhang Y, Han S, Hou B. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer. Expert Rev Anticancer Ther. 2020;20(12):1107–1119. doi:10.1080/14737140.2020.1838280
   PubMed Web of Science ®Google Scholar
• Alberti C. Genetic and microenvironmental implications in prostate cancer progression and metastasis. Eur Rev Med Pharmacol Sci. 2008;12(3):167–175.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int. 2012;110(2 Pt 2):E99–104. doi:10.1111/j.1464-410X.2011.10790.x
   PubMed Web of Science ®Google Scholar
• Lou DY, Fong L. Neoadjuvant therapy for localized prostate cancer: examining mechanism of action and efficacy within the tumor. Urol Oncol. 2016;34(4):182–192. doi:10.1016/j.urolonc.2013.12.001
   PubMed Web of Science ®Google Scholar
• Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer. 2012;12(4):289–297. doi:10.1038/nrc3223
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Revannasiddaiah S, Gupta I, Devadas SK. Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer. Chin Clin Oncol. 2019;8(S1):S13. doi:10.21037/cco.2019.01.07
   PubMed Web of Science ®Google Scholar
• Benzon B, Glavaris SA, Simons BW, et al. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):126–136. doi:10.1038/s41391-018-0035-z
   PubMed Web of Science ®Google Scholar